利妥昔单抗联合GDP方案治疗非霍奇金淋巴瘤患者的效果及对免疫功能的影响

Effect of rituximab combined with GDP regimen in the treatment of patients with non-Hodgkin's lymphoma and its influence on immune function

目的探讨利妥昔单抗联合吉西他滨+顺铂+地塞米松(GDP)方案治疗非霍奇金淋巴瘤患者的效果及对免疫功能的影响。方法选取2020年3月至2022年8月我院收治的106例非霍奇金淋巴瘤患者,根据治疗方案不同将其分为对照组(53例)和观察组(53例)。对照组采用GDP方案治疗,观察组在对照组基础上加用利妥昔单抗治疗。比较两组的治疗效果。结果观察组的疾病控制率(DCR)为96.23%,高于对照组的84.91%,差异具有统计学意义(P<0.05)。治疗后,观察组的免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、补体C3、补体C4、血管内皮生长因子(VEGF)及胸苷激酶-1(TK-1)水平均低于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论利妥昔单抗联合GDP方案治疗非霍奇金淋巴瘤患者效果显著,可改善免疫功能,降低血清肿瘤标志物水平,且用药安全性高。

Objective To investigate the effect of rituximab combined with gemcitabine+cisplatin+dexamethasone(GDP)regimen in the treatment of patients with non-Hodgkin's lymphoma and its influence on immune function.Methods A total of 106 patients with non-Hodgkin's lymphoma admitted in our hospital from March 2020 to August 2022 were selected and divided into control group(53 cases)and observation group(53 cases)according to different treatment schemes.The control group was treated with GDP regimen,and the observation group was treated with rituximab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The disease control rate(DCR)of the observation group was 96.23%,which was higher than 84.91%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM),complement C3,complement C4,vascular endothelial growth factor(VEGF)and thymidine kinase-1(TK-1)in the observation group were lower than those in the control group,and the difference were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rituximab combined with GDP regimen is effective in the treatment of patients with non-Hodgkin's lymphoma,it can improve immune function,reduce serum tumor markers levels,and has high drug safety.